Cardioxyl gains $14.5M in first venture round

Cardioxyl Pharmaceuticals of Towson, MD has pocketed $14.5 million in its first round of venture capital. Much of the money will go to developing its nitroxyl donor program for the treatment of acute decompensated heart failure. The Aurora Funds and New Enterprise Associates co-led the round. Cardioxyl's initial program is based on technology developed at Johns Hopkins University by David Kass, M.D., John P. Toscano, Ph.D., Nazareno Paolocci, M.D., Ph.D., and their scientific collaborators.

- here's the release on the venture round

ALSO: Aushon BioSystems of Burlington, MA, which provides microarray-based tools, instrumentation and services, has raised $7.78 million in their first round. Release

Suggested Articles

Merck’s TIGIT-blocking prospect and PD-1 med Keytruda shrank tumors in 29% of lung cancer patients who had never tried a checkpoint inhibitor.

Merck's HIF-2α inhibitor, picked up in its $1 billion Peloton buyout, shrank kidney tumors in 36% of patients and showed promise in other tumors, too.

Amunix reported that a single dose of its lead T-cell engager caused caused large HER2-positive tumors to shrink in mice.